Table of Content
1. Executive Summary | Hemophilia Treatment Market
1.1. Global Market Outlook
1.2. Summary of Statistics
1.3. Key Market Characteristics & Attributes
1.4. FMI Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Risks and Trends Assessment
3.1. Risk Assessment
3.1.1. COVID-19 Crisis and Impact on Demand
3.1.2. COVID-19 Impact Benchmark with Previous Crisis
3.1.3. Impact on Market Value (US$ Million)
3.1.4. Assessment by Key Countries
3.1.5. Assessment by Key Market Segments
3.1.6. Action Points and Recommendation for Suppliers
3.2. Key Trends Impacting the Market
3.3. Formulation and Product Development Trends
4. Market Background
4.1. By Country, US$ Million
4.2. Market Opportunity Assessment (US$ Million)
4.2.1. Total Available Market
4.2.2. Serviceable Addressable Market
4.2.3. Serviceable Obtainable Market
4.3. Market Scenario Forecast
4.3.1. Demand in Optimistic Scenario
4.3.2. Demand in Likely Scenario
4.3.3. Demand in Conservative Scenario
4.4. Investment Feasibility Analysis
4.4.1. Investment in Established Markets
4.4.1.1. In Short Term
4.4.1.2. In Long Term
4.4.2. Investment in Emerging Markets
4.4.2.1. In Short Term
4.4.2.2. In Long Term
4.5. Forecast Factors - Relevance & Imp
4.5.1. Top Companies Historical Growth
4.5.2. Global Growth
4.5.3. Adoption Rate, By Country
4.5.4. Investments in 3D Printing Technology
4.6. Market Dynamics
4.6.1. Market Driving Factors and Impact Assessment
4.6.2. Prominent Market Challenges and Impact Assessment
4.6.3. Market Opportunities
4.6.4. Prominent Trends in the Global Market & Their Impact Assessment
5. Key Success Factors
5.1. Manufacturers’ Focus on Low Penetration High Growth Markets
5.2. Banking on with Segments High Incremental Opportunity
5.3. Peer Benchmarking
6. Global Market Demand Analysis 2015 to 2021 and Forecast, 2022 to 2032
6.1. Historical Market Analysis, 2015 to 2021
6.2. Current and Future Market Projections, 2022 to 2032
6.3. Y-o-Y Growth Trend Analysis
7. Global Market Value Analysis 2015 to 2021 and Forecast, 2022 to 2032
7.1. Historical Market Value (US$ Million) Analysis, 2015 to 2021
7.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Disease
8.1. Introduction / Key Findings
8.2. Historical Market Value (US$ Million) and AnalysisBy Disease, 2015 to 2021
8.3. Current and Future Market Value (US$ Million) and Analysis and ForecastBy Disease, 2022 to 2032
8.3.1. Hemophilia A
8.3.1.1. Severe
8.3.1.2. Moderate
8.3.1.3. Mild
8.3.2. Hemophilia B
8.3.2.1. Severe
8.3.2.2. Moderate
8.3.2.3. Mild
8.4. Market Attractiveness AnalysisBy Disease
9. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Product
9.1. Introduction / Key Findings
9.2. Historical Market Value (US$ Million) and Analysis By Product, 2015 to 2021
9.3. Current and Future Market Value (US$ Million) and Analysis and Forecast By Product, 2022 to 2032
9.3.1. Recombinant Factor Concentrates
9.3.1.1. Factor VIII
9.3.1.2. Factor IX
9.3.2. Plasma-derived Factor Concentrates
9.3.2.1. Factor VIII
9.3.2.2. Factor IX
9.3.3. Extended Half-life Products
9.3.3.1. Factor VIII
9.3.3.2. Factor IX
9.3.4. Others
9.4. Market Attractiveness Analysis By Product
10. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Patient
10.1. Introduction / Key Findings
10.2. Historical Market Value (US$ Million) and Analysis By Patient, 2015 to 2021
10.3. Current and Future Market Value (US$ Million) and Analysis and Forecast By Patient, 2022 to 2032
10.3.1. Pediatric
10.3.1.1. 0 to 4
10.3.1.2. 5 to 13
10.3.1.3. 14 to18
10.3.2. Adult
10.3.2.1. 19 to 44
10.3.2.2. 45+
10.4. Market Attractiveness Analysis By Patient
11. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Treatment
11.1. Introduction / Key Findings
11.2. Historical Market Value (US$ Million) and Analysis By Deployment Mode, 2015 to 2021
11.3. Current and Future Market Value (US$ Million) and Analysis and Forecast By Deployment Mode, 2022 to 2032
11.3.1. Prophylaxis
11.3.2. On Demand
11.4. Market Attractiveness Analysis By Deployment Mode
12. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Therapy
12.1. Introduction / Key Findings
12.2. Historical Market Value (US$ Million) and Analysis By Therapy, 2015 to 2021
12.3. Current and Future Market Value (US$ Million) and Analysis and Forecast By Therapy, 2022 to 2032
12.3.1. Factor Replacement Therapy
12.3.2. Non-factor Replacement Therapy
12.4. Market Attractiveness Analysis By Therapy
13. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Drug Class
13.1. Introduction / Key Findings
13.2. Historical Market Value (US$ Million) and Analysis By Drug Class, 2015 to 2021
13.3. Current and Future Market Value (US$ Million) and Analysis and Forecast By Drug Class, 2022 to 2032
13.3.1. Vasopressin
13.3.2. Coagulation Factors
13.4. Market Attractiveness Analysis By Drug Class
14. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Route of Administration
14.1. Introduction / Key Findings
14.2. Historical Market Value (US$ Million) and Analysis By Route of Administration, 2015 to 2021
14.3. Current and Future Market Value (US$ Million) and Analysis and Forecast By Route of Administration, 2022 to 2032
14.3.1. Injectable
14.3.2. Nasal Spray
14.4. Market Attractiveness Analysis By Route of Administration
15. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Region
15.1. Introduction
15.2. Historical Market Value (US$ Million) and Analysis By Region, 2015 to 2021
15.3. Current Market Size (US$ Million) & Analysis and Forecast By Region, 2022 to 2032
15.3.1. North America
15.3.2. Latin America
15.3.3. Europe
15.3.4. Asia Pacific
15.3.5. Middle East and Africa (MEA)
15.4. Market Attractiveness Analysis By Region
16. North America Market Analysis 2015 to 2021 and Forecast 2022 to 2032
16.1. Introduction
16.2. Pricing Analysis
16.3. Historical Market Value (US$ Million) and Trend Analysis By Market Taxonomy, 2015 to 2021
16.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032
16.4.1. By Country
16.4.1.1. USA
16.4.1.2. Canada
16.4.2. By Patient
16.4.3. By Disease
16.4.4. By Product
16.4.5. By Treatment
16.4.6. By Therapy
16.4.7. By Route of Administration
16.4.8. By Drug Class
16.5. Market Attractiveness Analysis
16.5.1. By Country
16.5.2. By Patient
16.5.3. By Disease
16.5.4. By Product
16.5.5. By Treatment
16.5.6. By Therapy
16.5.7. By Route of Administration
16.5.8. By Drug Class
17. Latin America Market Analysis 2015 to 2021 and Forecast 2022 to 2032
17.1. Introduction
17.2. Pricing Analysis
17.3. Historical Market Value (US$ Million) and Trend Analysis By Market Taxonomy, 2015 to 2021
17.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032
17.4.1. By Country
17.4.1.1. Brazil
17.4.1.2. Mexico
17.4.1.3. Rest of Latin America
17.4.2. By Patient
17.4.3. By Disease
17.4.4. By Product
17.4.5. By Treatment
17.4.6. By Therapy
17.4.7. By Route of Administration
17.4.8. By Drug Class
17.5. Market Attractiveness Analysis
17.5.1. By Country
17.5.2. By Patient
17.5.3. By Disease
17.5.4. By Product
17.5.5. By Treatment
17.5.6. By Therapy
17.5.7. By Route of Administration
17.5.8. By Drug Class
18. Europe Market Analysis 2015 to 2021 and Forecast 2022 to 2032
18.1. Introduction
18.2. Pricing Analysis
18.3. Historical Market Value (US$ Million) and Trend Analysis By Market Taxonomy, 2015 to 2021
18.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032
18.4.1. By Country
18.4.1.1. Germany
18.4.1.2. France
18.4.1.3. United Kingdom
18.4.1.4. Italy
18.4.1.5. Russia
18.4.1.6. Rest of Europe
18.4.2. By Patient
18.4.3. By Disease
18.4.4. By Product
18.4.5. By Treatment
18.4.6. By Therapy
18.4.7. By Route of Administration
18.4.8. By Drug Class
18.5. Market Attractiveness Analysis
18.5.1. By Country
18.5.2. By Patient
18.5.3. By Disease
18.5.4. By Product
18.5.5. By Treatment
18.5.6. By Therapy
18.5.7. By Route of Administration
18.5.8. By Drug Class
19. Asia Pacific Market Analysis 2015 to 2021 and Forecast 2022 to 2032
19.1. Introduction
19.2. Pricing Analysis
19.3. Historical Market Value (US$ Million) and Trend Analysis By Market Taxonomy, 2015 to 2021
19.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032
19.4.1. By Country
19.4.1.1. China
19.4.1.2. Japan
19.4.1.3. South Korea
19.4.1.4. Rest of Asia Pacific
19.4.2. By Patient
19.4.3. By Disease
19.4.4. By Product
19.4.5. By Treatment
19.4.6. By Therapy
19.4.7. By Route of Administration
19.4.8. By Drug Class
19.5. Market Attractiveness Analysis
19.5.1. By Country
19.5.2. By Patient
19.5.3. By Disease
19.5.4. By Product
19.5.5. By Treatment
19.5.6. By Therapy
19.5.7. By Route of Administration
19.5.8. By Drug Class
20. Middle East and Africa Market Analysis 2015 to 2021 and Forecast 2022 to 2032
20.1. Introduction
20.2. Pricing Analysis
20.3. Historical Market Value (US$ Million) and Trend Analysis By Market Taxonomy, 2015 to 2021
20.4. Market Value (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032
20.4.1. By Country
20.4.1.1. GCC Countries
20.4.1.2. South Africa
20.4.1.3. Turkey
20.4.1.4. Rest of Middle East and Africa
20.4.2. By Patient
20.4.3. By Disease
20.4.4. By Product
20.4.5. By Treatment
20.4.6. By Therapy
20.4.7. By Route of Administration
20.4.8. By Drug Class
20.5. Market Attractiveness Analysis
20.5.1. By Country
20.5.2. By Patient
20.5.3. By Disease
20.5.4. By Product
20.5.5. By Treatment
20.5.6. By Therapy
20.5.7. By Route of Administration
20.5.8. By Drug Class
21. Key Countries Market Analysis 2015 to 2021 and Forecast 2022 to 2032
21.1. Introduction
21.1.1. Market Value Proportion Analysis, By Key Countries
21.1.2. Global Vs. Country Growth Comparison
21.2. USA Market Analysis
21.2.1. Value Proportion Analysis by Market Taxonomy
21.2.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032
21.2.2.1. By Patient
21.2.2.2. By Disease
21.2.2.3. By Product
21.2.2.4. By Treatment
21.2.2.5. By Therapy
21.2.2.6. By Route of Administration
21.2.2.7. By Drug Class
21.3. Canada Market Analysis
21.3.1. Value Proportion Analysis by Market Taxonomy
21.3.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032
21.3.2.1. By Patient
21.3.2.2. By Disease
21.3.2.3. By Product
21.3.2.4. By Treatment
21.3.2.5. By Therapy
21.3.2.6. By Route of Administration
21.3.2.7. By End-User
21.4. Mexico Market Analysis
21.4.1. Value Proportion Analysis by Market Taxonomy
21.4.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032
21.4.2.1. By Patient
21.4.2.2. By Disease
21.4.2.3. By Product
21.4.2.4. By Treatment
21.4.2.5. By Therapy
21.4.2.6. By Route of Administration
21.4.2.7. By End-User
21.5. Brazil Market Analysis
21.5.1. Value Proportion Analysis by Market Taxonomy
21.5.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032
21.5.2.1. By Patient
21.5.2.2. By Disease
21.5.2.3. By Product
21.5.2.4. By Treatment
21.5.2.5. By Therapy
21.5.2.6. By Route of Administration
21.5.2.7. By End-User
21.6. Germany Market Analysis
21.6.1. Value Proportion Analysis by Market Taxonomy
21.6.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032
21.6.2.1. By Patient
21.6.2.2. By Disease
21.6.2.3. By Product
21.6.2.4. By Treatment
21.6.2.5. By Therapy
21.6.2.6. By Route of Administration
21.6.2.7. By End-User
21.7. France Market Analysis
21.7.1. Value Proportion Analysis by Market Taxonomy
21.7.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032
21.7.2.1. By Patient
21.7.2.2. By Disease
21.7.2.3. By Product
21.7.2.4. By Treatment
21.7.2.5. By Therapy
21.7.2.6. By Route of Administration
21.7.2.7. By End-User
21.8. Italy Market Analysis
21.8.1. Value Proportion Analysis by Market Taxonomy
21.8.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032
21.8.2.1. By Patient
21.8.2.2. By Disease
21.8.2.3. By Product
21.8.2.4. By Treatment
21.8.2.5. By Therapy
21.8.2.6. By Route of Administration
21.8.2.7. By End-User
21.9. Russia Market Analysis
21.9.1. Value Proportion Analysis by Market Taxonomy
21.9.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032
21.9.2.1. By Patient
21.9.2.2. By Disease
21.9.2.3. By Product
21.9.2.4. By Treatment
21.9.2.5. By Therapy
21.9.2.6. By Route of Administration
21.9.2.7. By End-User
21.10. UK Market Analysis
21.10.1. Value Proportion Analysis by Market Taxonomy
21.10.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032
21.10.2.1. By Patient
21.10.2.2. By Disease
21.10.2.3. By Product
21.10.2.4. By Treatment
21.10.2.5. By Therapy
21.10.2.6. By Route of Administration
21.10.2.7. By End-User
21.11. China Market Analysis
21.11.1. Value Proportion Analysis by Market Taxonomy
21.11.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032
21.11.2.1. By Patient
21.11.2.2. By Disease
21.11.2.3. By Product
21.11.2.4. By Treatment
21.11.2.5. By Therapy
21.11.2.6. By Route of Administration
21.11.2.7. By End-User
21.12. Japan Market Analysis
21.12.1. Value Proportion Analysis by Market Taxonomy
21.12.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032
21.12.2.1. By Patient
21.12.2.2. By Disease
21.12.2.3. By Product
21.12.2.4. By Treatment
21.12.2.5. By Therapy
21.12.2.6. By Route of Administration
21.12.2.7. By End-User
21.13. South Korea Market Analysis
21.13.1. Value Proportion Analysis by Market Taxonomy
21.13.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032
21.13.2.1. By Patient
21.13.2.2. By Disease
21.13.2.3. By Product
21.13.2.4. By Treatment
21.13.2.5. By Therapy
21.13.2.6. By Route of Administration
21.13.2.7. By End-User
21.14. GCC Countries Market Analysis
21.14.1. Value Proportion Analysis by Market Taxonomy
21.14.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032
21.14.2.1. By Patient
21.14.2.2. By Disease
21.14.2.3. By Product
21.14.2.4. By Treatment
21.14.2.5. By Therapy
21.14.2.6. By Route of Administration
21.14.2.7. By End-User
21.15. South Africa Market Analysis
21.15.1. Value Proportion Analysis by Market Taxonomy
21.15.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032
21.15.2.1. By Patient
21.15.2.2. By Disease
21.15.2.3. By Product
21.15.2.4. By Treatment
21.15.2.5. By Therapy
21.15.2.6. By Route of Administration
21.15.2.7. By End-User
21.16. Turkey Market Analysis
21.16.1. Value Proportion Analysis by Market Taxonomy
21.16.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032
21.16.2.1. By Patient
21.16.2.2. By Disease
21.16.2.3. By Product
21.16.2.4. By Treatment
21.16.2.5. By Therapy
21.16.2.6. By Route of Administration
21.16.2.7. By End-User
21.16.3. Competition Landscape and Player Concentration in the Country
22. Market Structure Analysis
22.1. Market Analysis by Tier of Companies
22.2. Market Concentration
22.3. Market Share Analysis of Top Players
22.4. Market Presence Analysis
22.4.1. By Regional Footprint of Players
22.4.2. Product Footprint by Players
23. Competition Analysis
23.1. Competition Dashboard
23.2. Competition Benchmarking
23.3. Competition Deep Dive
23.3.1. Bayer Healthcare
23.3.1.1. Overview
23.3.1.2. Product Portfolio
23.3.1.3. Sales Footprint
23.3.1.4. Strategy Overview
23.3.2. Biogen
23.3.2.1. Overview
23.3.2.2. Product Portfolio
23.3.2.3. Sales Footprint
23.3.2.4. Strategy Overview
23.3.3. Biotest AG
23.3.3.1. Overview
23.3.3.2. Product Portfolio
23.3.3.3. Sales Footprint
23.3.3.4. Strategy Overview
23.3.4. CSL Behring
23.3.4.1. Overview
23.3.4.2. Product Portfolio
23.3.4.3. Sales Footprint
23.3.4.4. Strategy Overview
23.3.5. Ferring B.V
23.3.5.1. Overview
23.3.5.2. Product Portfolio
23.3.5.3. Sales Footprint
23.3.5.4. Strategy Overview
23.3.6. Genentech
23.3.6.1. Overview
23.3.6.2. Product Portfolio
23.3.6.3. Sales Footprint
23.3.6.4. Strategy Overview
23.3.7. Kedrion
23.3.7.1. Overview
23.3.7.2. Product Portfolio
23.3.7.3. Sales Footprint
23.3.7.4. Strategy Overview
23.3.8. Novo Nordisk
23.3.8.1. Overview
23.3.8.2. Product Portfolio
23.3.8.3. Sales Footprint
23.3.8.4. Strategy Overview
23.3.9. Octapharma
23.3.9.1. Overview
23.3.9.2. Product Portfolio
23.3.9.3. Sales Footprint
23.3.9.4. Strategy Overview
23.3.10. Pfizer
23.3.10.1. Overview
23.3.10.2. Product Portfolio
23.3.10.3. Sales Footprint
23.3.10.4. Strategy Overview
24. Assumptions and Acronyms Used
25. Research Methodology
List of Tables
Table 1: Global Market Value (US$ Million), By Patient, 2015 to 2021
Table 2: Global Market Value (US$ Million), By Patient, 2022 to 2032
Table 3: Global Market Value (US$ Million), By Disease, 2015 to 2021
Table 4: Global Market Value (US$ Million), By Disease, 2022 to 2032
Table 5: Global Market Value (US$ Million), By Product, 2015 to 2021
Table 6: Global Market Value (US$ Million), By Product, 2022 to 2032
Table 7: Global Market Value (US$ Million), By Therapy, 2015 to 2021
Table 8: Global Market Value (US$ Million), By Therapy, 2022 to 2032
Table 9: Global Market Value (US$ Million), By Route of Administration, 2015 to 2021
Table 10: Global Market Value (US$ Million), By Route of Administration, 2022 to 2032
Table 11: Global Market Value (US$ Million), By Deployment Mode, 2015 to 2021
Table 12: Global Market Value (US$ Million), By Deployment Mode, 2022 to 2032
Table 13: Global Market Value (US$ Million), By End-User, 2015 to 2021
Table 14: Global Market Value (US$ Million), By End-User, 2022 to 2032
Table 15: Global Market, By Region, 2015 to 2021
Table 16: Global Market, By Region, 2022 to 2032
Table 17: North America Market Value (US$ Million), By Patient, 2015 to 2021
Table 18: North America Market Value (US$ Million), By Patient, 2022 to 2032
Table 19: North America Market Value (US$ Million), By Disease, 2015 to 2021
Table 20: North America Market Value (US$ Million), By Disease, 2022 to 2032
Table 21: North America Market Value (US$ Million), By Product, 2015 to 2021
Table 22: North America Market Value (US$ Million), By Product, 2022 to 2032
Table 23: North America Market Value (US$ Million), By Therapy, 2015 to 2021
Table 24: North America Market Value (US$ Million), By Therapy, 2022 to 2032
Table 25: North America Market Value (US$ Million), By Route of Administration, 2015 to 2021
Table 26: North America Market Value (US$ Million), By Route of Administration, 2022 to 2032
Table 27: North America Market Value (US$ Million), By Deployment Mode, 2015 to 2021
Table 28: North America Market Value (US$ Million), By Deployment Mode, 2022 to 2032
Table 29: North America Market Value (US$ Million), By End-User, 2015 to 2021
Table 30: North America Market Value (US$ Million), By End-User, 2022 to 2032
Table 31: North America Market, By Country, 2015 to 2021
Table 32: North America Market, By Country, 2022 to 2032
Table 33: Latin America Market Value (US$ Million), By Patient, 2015 to 2021
Table 34: Latin America Market Value (US$ Million), By Patient, 2022 to 2032
Table 35: Latin America Market Value (US$ Million), By Disease, 2015 to 2021
Table 36: Latin America Market Value (US$ Million), By Disease, 2022 to 2032
Table 37: Latin America Market Value (US$ Million), By Product, 2015 to 2021
Table 38: Latin America Market Value (US$ Million), By Product, 2022 to 2032
Table 39: Latin America Market Value (US$ Million), By Therapy, 2015 to 2021
Table 40: Latin America Market Value (US$ Million), By Therapy, 2022 to 2032
Table 41: Latin America Market Value (US$ Million), By Route of Administration, 2015 to 2021
Table 42: Latin America Market Value (US$ Million), By Route of Administration, 2022 to 2032
Table 43: Latin America Market Value (US$ Million), By Deployment Mode, 2015 to 2021
Table 44: Latin America Market Value (US$ Million), By Deployment Mode, 2022 to 2032
Table 45: Latin America Market Value (US$ Million), By End-User2015 to 2021
Table 46: Latin America Market Value (US$ Million), By End-User, 2022 to 2032
Table 47: Latin America Market, By Country, 2015 to 2021
Table 48: Latin America Market, By Country, 2022 to 2032
Table 49: Europe Market Value (US$ Million), By Patient, 2015 to 2021
Table 50: Europe Market Value (US$ Million), By Patient, 2022 to 2032
Table 51: Europe Market Value (US$ Million), By Disease, 2015 to 2021
Table 52: Europe Market Value (US$ Million), By Disease, 2022 to 2032
Table 53: Europe Market Value (US$ Million), By Product, 2015 to 2021
Table 54: Europe Market Value (US$ Million), By Product, 2022 to 2032
Table 55: Europe Market Value (US$ Million), By Therapy, 2015 to 2021
Table 56: Europe Market Value (US$ Million), By Therapy, 2022 to 2032
Table 57: Europe Market Value (US$ Million), By Route of Administration, 2015 to 2021
Table 58: Europe Market Value (US$ Million), By Route of Administration, 2022 to 2032
Table 59: Europe Market Value (US$ Million), By Deployment Mode, 2015 to 2021
Table 60: Europe Market Value (US$ Million), By Deployment Mode, 2022 to 2032
Table 61: Europe Market Value (US$ Million), By End-User, 2015 to 2021
Table 62: Europe Market Value (US$ Million), By End-User, 2022 to 2032
Table 63: Europe Market, By Country, 2015 to 2021
Table 64: Europe Market, By Country, 2022 to 2032
Table 65: Asia Pacific Market Value (US$ Million), By Patient, 2015 to 2021
Table 66: Asia Pacific Market Value (US$ Million), By Patient, 2022 to 2032
Table 67: Asia Pacific Market Value (US$ Million), By Disease, 2015 to 2021
Table 68: Asia Pacific Market Value (US$ Million), By Disease, 2022 to 2032
Table 69: Asia Pacific Market Value (US$ Million), By Product, 2015 to 2021
Table 70: Asia Pacific Market Value (US$ Million), By Product, 2022 to 2032
Table 71: Asia Pacific Market Value (US$ Million), By Therapy, 2015 to 2021
Table 72: Asia Pacific Market Value (US$ Million), By Therapy, 2022 to 2032
Table 73: Asia Pacific Market Value (US$ Million), By Route of Administration, 2015 to 2021
Table 74: Asia Pacific Market Value (US$ Million), By Route of Administration, 2022 to 2032
Table 75: Asia Pacific Market Value (US$ Million), By Deployment Mode, 2015 to 2021
Table 76: Asia Pacific Market Value (US$ Million), By Deployment Mode, 2022 to 2032
Table 77: Asia Pacific Market Value (US$ Million), By End-User, 2015 to 2021
Table 78: Asia Pacific Market Value (US$ Million), By End-User, 2022 to 2032
Table 79: Asia Pacific Market, By Country, 2015 to 2021
Table 80: Asia Pacific Market, By Country, 2022 to 2032
Table 81: MEA Market Value (US$ Million), By Patient, 2015 to 2021
Table 82: MEA Market Value (US$ Million), By Patient, 2022 to 2032
Table 83: MEA Market Value (US$ Million), By Disease, 2015 to 2021
Table 84: MEA Market Value (US$ Million), By Disease, 2022 to 2032
Table 85: MEA Market Value (US$ Million), By Product, 2015 to 2021
Table 86: MEA Market Value (US$ Million), By Product, 2022 to 2032
Table 87: MEA Market Value (US$ Million), By Therapy, 2015 to 2021
Table 88: MEA Market Value (US$ Million), By Therapy, 2022 to 2032
Table 89: MEA Market Value (US$ Million), By Route of Administration, 2015 to 2021
Table 90: MEA Market Value (US$ Million), By Route of Administration, 2022 to 2032
Table 91: MEA Market Value (US$ Million), By Deployment Mode, 2015 to 2021
Table 92: MEA Market Value (US$ Million), By Deployment Mode, 2022 to 2032
Table 93: MEA Market Value (US$ Million), By End-User, 2015 to 2021
Table 94: MEA Market Value (US$ Million), By Drug Class 2022 to 2032
Table 95: MEA Market, By Country, 2015 to 2021
Table 96: MEA Market, By Country, 2022 to 2032
List of Charts
Figure 1: Global Market Value (US$ Million) and Year-on-Year Growth, 2015 to 2032
Figure 2: Global Market Absolute $ Historical Gain (2015 to 2021) and Opportunity (2022 to 2032), US$ Million
Figure 3: Global Market Share, By Patient, 2022 & 2032
Figure 4: Global Market Y-o-Y Growth Projections, By Patient – 2022 to 2032
Figure 5: Global Market Attractiveness Index, By Patient – 2022 to 2032
Figure 6: Global Market Share, By Disease, 2022 & 2032
Figure 7: Global Market Y-o-Y Growth Projections, By Disease – 2022 to 2032
Figure 8: Global Market Attractiveness Index, By Disease – 2022 to 2032
Figure 9: Global Market Share, By Therapy, 2022 & 2032
Figure 10: Global Market Y-o-Y Growth Projections, By Therapy – 2022 to 2032
Figure 11: Global Market Attractiveness Index, By Therapy – 2022 to 2032
Figure 12: Global Market Share, By Route of Administration, 2022 & 2032
Figure 13: Global Market Y-o-Y Growth Projections, By Route of Administration – 2022 to 2032
Figure 14: Global Market Attractiveness Index, By Route of Administration – 2022 to 2032
Figure 15: Global Market Share, By Product, 2022 & 2032
Figure 16: Global Market Y-o-Y Growth Projections, By Product – 2022 to 2032
Figure 17: Global Market Attractiveness Index, By Product – 2022 to 2032
Figure 18: Global Market Share, By Deployment Mode, 2022 & 2032
Figure 19: Global Market Y-o-Y Growth Projections, By Treatment – 2022 to 2032
Figure 20: Global Market Attractiveness Index, By Treatment – 2022 to 2032
Figure 21: Global Market Share, By End-User, 2022 & 2032
Figure 22: Global Market Y-o-Y Growth Projections, By Drug Class – 2022 to 2032
Figure 23: Global Market Y-o-Y Growth Projections, By End-User– 2022 to 2032
Figure 24: Global Market Share, By Region, 2022 & 2032
Figure 25: Global Market Y-o-Y Growth Projections, By Region – 2022 to 2032
Figure 26: Global Market Attractiveness Index, By Region – 2022 to 2032
Figure 27: North America Market Value (US$ Million) and Year-on-Year Growth, 2015 to 2032
Figure 28: North America Market Absolute $ Historical Gain (2015 to 2021) and Opportunity (2022 to 2032), US$ Million
Figure 29: North America Market Share, By Patient, 2022 & 2032
Figure 30: North America Market Y-o-Y Growth Projections, By Patient – 2022 to 2032
Figure 31: North America Market Attractiveness Index, By Patient – 2022 to 2032
Figure 32: North America Market Share, By Disease, 2022 & 2032
Figure 33: North America Market Y-o-Y Growth Projections, By Disease – 2022 to 2032
Figure 34: North America Market Attractiveness Index, By Disease – 2022 to 2032
Figure 35: North America Market Share, By Therapy, 2022 & 2032
Figure 36: North America Market Y-o-Y Growth Projections, By Therapy – 2022 to 2032
Figure 37: North America Market Attractiveness Index, By Therapy – 2022 to 2032
Figure 38: North America Market Share, By Route of Administration, 2022 & 2032
Figure 39: North America Market Y-o-Y Growth Projections, By Route of Administration – 2022 to 2032
Figure 40: North America Market Attractiveness Index, By Route of Administration – 2022 to 2032
Figure 41: North America Market Share, By Product, 2022 & 2032
Figure 42: North America Market Y-o-Y Growth Projections, By Product – 2022 to 2032
Figure 43: North America Market Attractiveness Index, By Product – 2022 to 2032
Figure 44: North America Market Share, By Deployment Mode, 2022 & 2032
Figure 45: North America Market Y-o-Y Growth Projections, By Treatment – 2022 to 2032
Figure 46: North America Market Attractiveness Index, By Treatment – 2022 to 2032
Figure 47: North America Market Share, By End-User, 2022 & 2032
Figure 48: North America Market Y-o-Y Growth Projections, By Drug Class – 2022 to 2032
Figure 49: North America Market Attractiveness Index, By Drug Class – 2022 to 2032
Figure 50: North America Market Share, By Country, 2022 & 2032
Figure 51: North America Market Y-o-Y Growth Projections, By Country – 2022 to 2032
Figure 52: North America Market Attractiveness Index, By Country – 2022 to 2032
Figure 53: Latin America Market Value (US$ Million) and Year-on-Year Growth, 2015 to 2032
Figure 54: Latin America Market Absolute $ Historical Gain (2015 to 2021) and Opportunity (2022 to 2032), US$ Million
Figure 55: Latin America Market Share, By Patient, 2022 & 2032
Figure 56: Latin America Market Y-o-Y Growth Projections, By Patient – 2022 to 2032
Figure 57: Latin America Market Attractiveness Index, By Patient – 2022 to 2032
Figure 58: Latin America Market Share, By Disease, 2022 & 2032
Figure 59: Latin America Market Y-o-Y Growth Projections, By Disease – 2022 to 2032
Figure 60: Latin America Market Attractiveness Index, By Disease – 2022 to 2032
Figure 61: Latin America Market Share, By Therapy, 2022 & 2032
Figure 62: Latin America Market Y-o-Y Growth Projections, By Therapy – 2022 to 2032
Figure 63: Latin America Market Attractiveness Index, By Therapy – 2022 to 2032
Figure 64: Latin America Market Share, By Route of Administration, 2022 & 2032
Figure 65: Latin America Market Y-o-Y Growth Projections, By Route of Administration – 2022 to 2032
Figure 66: Latin America Market Attractiveness Index, By Route of Administration – 2022 to 2032
Figure 67: Latin America Market Share, By Product, 2022 & 2032
Figure 68: Latin America Market Y-o-Y Growth Projections, By Product – 2022 to 2032
Figure 69: Latin America Market Attractiveness Index, By Product – 2022 to 2032
Figure 70: Latin America Market Share, By Deployment Mode, 2022 & 2032
Figure 71: Latin America Market Y-o-Y Growth Projections, By Treatment – 2022 to 2032
Figure 72: Latin America Market Attractiveness Index, By Treatment – 2022 to 2032
Figure 73: Latin America Market Share, By End-User, 2022 & 2032
Figure 74: Latin America Market Y-o-Y Growth Projections, By Drug Class – 2022 to 2032
Figure 75: Latin America Market Attractiveness Index, By Drug Class – 2022 to 2032
Figure 76: Latin America Market Share, By Country, 2022 & 2032
Figure 77: Latin America Market Y-o-Y Growth Projections, By Country – 2022 to 2032
Figure 78: Latin America Market Attractiveness Index, By Country – 2022 to 2032
Figure 79: Europe Market Value (US$ Million) and Year-on-Year Growth, 2015 to 2032
Figure 80: Europe Market Absolute $ Historical Gain (2015 to 2021) and Opportunity (2022 to 2032), US$ Million
Figure 81: Europe Market Share, By Patient, 2022 & 2032
Figure 82: Europe Market Y-o-Y Growth Projections, By Patient – 2022 to 2032
Figure 83: Europe Market Attractiveness Index, By Patient – 2022 to 2032
Figure 84: Europe Market Share, By Disease, 2022 & 2032
Figure 85: Europe Market Y-o-Y Growth Projections, By Disease – 2022 to 2032
Figure 86: Europe Market Attractiveness Index, By Disease – 2022 to 2032
Figure 87: Europe Market Share, By Therapy, 2022 & 2032
Figure 88: Europe Market Y-o-Y Growth Projections, By Therapy – 2022 to 2032
Figure 89: Europe Market Attractiveness Index, By Therapy – 2022 to 2032
Figure 90: Europe Market Share, By Route of Administration, 2022 & 2032
Figure 91: Europe Market Y-o-Y Growth Projections, By Route of Administration – 2022 to 2032
Figure 92: Europe Market Attractiveness Index, By Route of Administration – 2022 to 2032
Figure 93: Europe Market Share, By Product, 2022 & 2032
Figure 94: Europe Market Y-o-Y Growth Projections, By Product – 2022 to 2032
Figure 95: Europe Market Attractiveness Index, By Product – 2022 to 2032
Figure 96: Europe Market Share, By Deployment Mode, 2022 & 2032
Figure 97: Europe Market Y-o-Y Growth Projections, By Treatment – 2022 to 2032
Figure 98: Europe Market Attractiveness Index, By Treatment – 2022 to 2032
Figure 99: Europe Market Share, By End-User, 2022 & 2032
Figure 100: Europe Market Y-o-Y Growth Projections, By Drug Class – 2022 to 2032
Figure 101: Europe Market Attractiveness Index, By Drug Class – 2022 to 2032
Figure 102: Europe Market Share, By Country, 2022 & 2032
Figure 103: Europe Market Y-o-Y Growth Projections, By Country – 2022 to 2032
Figure 104: Europe Market Attractiveness Index, By Country – 2022 to 2032
Figure 105: Asia Pacific Market Value (US$ Million) and Year-on-Year Growth, 2015 to 2032
Figure 106: Asia Pacific Market Absolute $ Historical Gain (2015 to 2021) and Opportunity (2022 to 2032), US$ Million
Figure 107: Asia Pacific Market Share, By Patient, 2022 & 2032
Figure 108: Asia Pacific Market Y-o-Y Growth Projections, By Patient – 2022 to 2032
Figure 109: Asia Pacific Market Attractiveness Index, By Patient – 2022 to 2032
Figure 110: Asia Pacific Market Share, By Disease, 2022 & 2032
Figure 111: Asia Pacific Market Y-o-Y Growth Projections, By Disease – 2022 to 2032
Figure 112: Asia Pacific Market Attractiveness Index, By Disease – 2022 to 2032
Figure 113: Asia Pacific Market Share, By Therapy, 2022 & 2032
Figure 114: Asia Pacific Market Y-o-Y Growth Projections, By Therapy – 2022 to 2032
Figure 115: Asia Pacific Market Attractiveness Index, By Therapy – 2022 to 2032
Figure 116: Asia Pacific Market Share, By Route of Administration, 2022 & 2032
Figure 117: Asia Pacific Market Y-o-Y Growth Projections, By Route of Administration – 2022 to 2032
Figure 118: Asia Pacific Market Attractiveness Index, By Route of Administration – 2022 to 2032
Figure 119: Asia Pacific Market Share, By Product, 2022 & 2032
Figure 120: Asia Pacific Market Y-o-Y Growth Projections, By Product – 2022 to 2032
Figure 121: Asia Pacific Market Attractiveness Index, By Product – 2022 to 2032
Figure 122: Asia Pacific Market Share, By Deployment Mode, 2022 & 2032
Figure 123: Asia Pacific Market Y-o-Y Growth Projections, By Treatment – 2022 to 2032
Figure 124: Asia Pacific Market Attractiveness Index, By Treatment – 2022 to 2032
Figure 125: Asia Pacific Market Share, By End-User, 2022 & 2032
Figure 126: Asia Pacific Market Y-o-Y Growth Projections, By Drug Class – 2022 to 2032
Figure 127: Asia Pacific Market Attractiveness Index, By Drug Class – 2022 to 2032
Figure 128: Asia Pacific Market Share, By Country, 2022 & 2032
Figure 129: Asia Pacific Market Y-o-Y Growth Projections, By Country – 2022 to 2032
Figure 130: Asia Pacific Market Attractiveness Index, By Country – 2022 to 2032
Figure 131: MEA Market Value (US$ Million) and Year-on-Year Growth, 2015 to 2032
Figure 132: MEA Market Absolute $ Historical Gain (2015 to 2021) and Opportunity (2022 to 2032), US$ Million
Figure 133: MEA Market Share, By Patient, 2022 & 2032
Figure 134: MEA Market Y-o-Y Growth Projections, By Patient – 2022 to 2032
Figure 135: MEA Market Attractiveness Index, By Patient – 2022 to 2032
Figure 136: MEA Market Share, By Disease, 2022 & 2032
Figure 137: MEA Market Y-o-Y Growth Projections, By Disease – 2022 to 2032
Figure 138: MEA Market Attractiveness Index, By Disease – 2022 to 2032
Figure 139: MEA Market Share, By Therapy, 2022 & 2032
Figure 140: MEA Market Y-o-Y Growth Projections, By Therapy – 2022 to 2032
Figure 141: MEA Market Attractiveness Index, By Therapy – 2022 to 2032
Figure 142: MEA Market Share, By Route of Administration, 2022 & 2032
Figure 143: MEA Market Y-o-Y Growth Projections, By Route of Administration – 2022 to 2032
Figure 144: MEA Market Attractiveness Index, By Route of Administration – 2022 to 2032
Figure 145: MEA Market Share, By Product, 2022 & 2032
Figure 146: MEA Market Y-o-Y Growth Projections, By Product – 2022 to 2032
Figure 147: MEA Market Attractiveness Index, By Product – 2022 to 2032
Figure 148: MEA Market Share, By Deployment Mode, 2022 & 2032
Figure 149: MEA Market Y-o-Y Growth Projections, By Treatment – 2022 to 2032
Figure 150: MEA Market Attractiveness Index, By Treatment – 2022 to 2032
Figure 151: MEA Market Share, By Drug Class 2022 & 2032
Figure 152: MEA Market Y-o-Y Growth Projections, By End-User– 2022 to 2032
Figure 153: MEA Market Attractiveness Index, By End-User– 2022 to 2032
Figure 154: MEA Market Share, By Country, 2022 & 2032
Figure 155: MEA Market Y-o-Y Growth Projections, By Country – 2022 to 2032
Figure 156: MEA Market Attractiveness Index, By Country – 2022 to 2032
